<DOC>
	<DOC>NCT02686385</DOC>
	<brief_summary>Intervention - Subjects will be randomized to 2 groups Group A - subjects will receive Prednisolone for 20 days with NAC (N-Acetylcysteine) Group B - will receive NAC (N-Acetylcysteine) only NAC (N-acetylcysteine) dosing Loading dose: 150 mg/kg IV; mix in 200 mL of 5% dextrose in water (D5W) and infuse over 1 hour Dose 2: 50 mg/kg IV in 500 mL D5W over 4 h Dose 3: 100 mg/kg IV in 1000 mL D5W over 16 h - Monitoring and assessment-Liver Biopsy at baseline and at 3 months, Liver Function Test at regular intervals. - Stopping rule-Development of sepsis, worsening of Liver functions.</brief_summary>
	<brief_title>Efficacy of N-acetylcysteine With or Without Steroids in Drug Induced Liver Injury</brief_title>
	<detailed_description />
	<mesh_term>Wounds and Injuries</mesh_term>
	<mesh_term>Drug-Induced Liver Injury</mesh_term>
	<mesh_term>Acetylcysteine</mesh_term>
	<mesh_term>N-monoacetylcystine</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>All patients with severe DILI (Drug Induced Liver Injury) Age more than or equal to 18 years Patients with HAV (Hepatitis A Virus), HBV (Hepatitis B Virus), HCV (Hepatitis C Virus), HEV (Hepatitis E Virus) Positive Patients with sepsis AMA positive Low Ceruloplasmin Transferrin saturation &gt;45% Patients with Cirrhosis Patients with h/o jaundice prior to the intake of drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>